Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI105572

A Comparison of the Metabolism of Radioactive 17-Isoaldosterone and Aldosterone Administered Intravenously and Orally to Normal Human Subjects

C. Flood, G. Pincus, J. F. Tait, S. A. S. Tait, and S. Willoughby

Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

†

Holder of Career Award GM-K6-18322. Address requests for reprints to Dr. James F. Tait, The Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

*

Submitted for publication November 2, 1966; accepted January 4, 1967.

Supported by U. S. Public Health Service grants AM-03179 and AM-06294 and a grant from the Atomic Energy Commission (30-1)-918.

Find articles by Flood, C. in: PubMed | Google Scholar

Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

†

Holder of Career Award GM-K6-18322. Address requests for reprints to Dr. James F. Tait, The Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

*

Submitted for publication November 2, 1966; accepted January 4, 1967.

Supported by U. S. Public Health Service grants AM-03179 and AM-06294 and a grant from the Atomic Energy Commission (30-1)-918.

Find articles by Pincus, G. in: PubMed | Google Scholar

Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

†

Holder of Career Award GM-K6-18322. Address requests for reprints to Dr. James F. Tait, The Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

*

Submitted for publication November 2, 1966; accepted January 4, 1967.

Supported by U. S. Public Health Service grants AM-03179 and AM-06294 and a grant from the Atomic Energy Commission (30-1)-918.

Find articles by Tait, J. in: PubMed | Google Scholar

Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

†

Holder of Career Award GM-K6-18322. Address requests for reprints to Dr. James F. Tait, The Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

*

Submitted for publication November 2, 1966; accepted January 4, 1967.

Supported by U. S. Public Health Service grants AM-03179 and AM-06294 and a grant from the Atomic Energy Commission (30-1)-918.

Find articles by Tait, S. in: PubMed | Google Scholar

Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

†

Holder of Career Award GM-K6-18322. Address requests for reprints to Dr. James F. Tait, The Worcester Foundation for Experimental Biology, Shrewsbury, Mass.

*

Submitted for publication November 2, 1966; accepted January 4, 1967.

Supported by U. S. Public Health Service grants AM-03179 and AM-06294 and a grant from the Atomic Energy Commission (30-1)-918.

Find articles by Willoughby, S. in: PubMed | Google Scholar

Published May 1, 1967 - More info

Published in Volume 46, Issue 5 on May 1, 1967
J Clin Invest. 1967;46(5):717–727. https://doi.org/10.1172/JCI105572.
© 1967 The American Society for Clinical Investigation
Published May 1, 1967 - Version history
View PDF
Abstract

After intravenous and oral administration of radioactive aldosterone to normal subjects, 7.3 ± 0.4 (SE) and 5.4 ± 0.5 (SE)%, respectively, of the dose was recovered from a 48-hour collection of urine as aldosterone released by mild acid hydrolysis (from aldosterone 18-glucuronide), and 35 ± 5 (SE) and 39 ± 4 (SE)%, respectively, was recovered as tetrahydroaldosterone after incubation with β-glucuronidase.

After intravenous and oral administration of 17-isoaldosterone-4-14C to a similar group of subjects, 35 ± 3 (SE) and 53 ± 4 (SE)%, respectively, of the dose was recovered as 17-isoaldosterone released by acid and less than 5% as total metabolites after incubation with β-glucuronidase. No detectable radioactivity (< 0.5%) could be recovered as tetrahydroaldosterone or as a compound with the expected chromatographic properties of tetrahydro-17-isoaldosterone.

The total radioactivity in the neutral extracts was also relatively small (< 2%) after administration of either labeled aldosterone or 17-isoaldosterone. The radioactivity as aldosterone in the neutral extract was much lower after oral [0.017 ± 0.003 (SE)%] than after intravenous [0.21 ± 0.04 (SE)%] administration of labeled aldosterone. The radioactivity as 17-isoaldosterone in the neutral extract was similar after intravenous [0.20 ± 0.02 (SE)%] and after oral [0.38 ± 0.18 (SE)%] administration of 17-isoaldosterone.

These results indicated that, due to lack of A-ring reduction of the molecule and the consequent slowing of hepatic clearance, 17-isoaldosterone is converted to an acid-labile conjugate (presumably 17-isoaldosterone 18-glucuronide) as the major metabolite. 17-Isoaldosterone was not secreted or converted to aldosterone to any significant extent in the normal subjects investigated.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 717
page 717
icon of scanned page 718
page 718
icon of scanned page 719
page 719
icon of scanned page 720
page 720
icon of scanned page 721
page 721
icon of scanned page 722
page 722
icon of scanned page 723
page 723
icon of scanned page 724
page 724
icon of scanned page 725
page 725
icon of scanned page 726
page 726
icon of scanned page 727
page 727
Version history
  • Version 1 (May 1, 1967): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts